Ultragenyx Pharmaceutical Inc at Bank of America Global Healthcare Conference Transcript
(audio in progress) I'm one of the biotech analysts here at BofA. Our next presenting company is Ultragenyx. And here with me are Howard Horn, Chief Financial Officer; and Josh Higa, Head of IR. Thanks for joining us, guys.
So I think there's a lot going on at the company. I think most people are familiar with it, but maybe we can start with a quick overview of the company, kind of your commercial products, and you have a very busy second-half of the year. So maybe you can highlight some of the key catalysts coming up.
Sure, glad to, and thank you for having us.
So Ultragenyx is a next-generation rare disease company on a pathway to profitability in 2027. We have four commercialized products, and we are estimating between $730 million and $760 million in revenue this year.
We are hopeful to have two approvals and launches of two gene therapy programs this year. And the other data event people are waiting
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
